WHAT IS ISBT 128?

WHO USES ISBT 128?

A Unifying Standard

Approved by the ISBT Council in 1994, the ISBT 128 Standard has gained international acceptance. Its use for Cellular Therapy products is supported by the boards of the AABB, ASFA, ASBMT, EBMT, FACT, ISBT, ISCT, ISCT Europe, JACIE, NMDP, and WMDA.

Facilities across six continents are registered to use ISBT 128. There are over 5,700 active registered facilities worldwide. 

COUNTRIES WITH ACTIVE REGISTERED FACILITIES
Andorra
Angola
Argentina
Aruba
Australia
Austria
Bahrain
Belgium
Botswana
Brazil
Canada
Cayman Islands
Chile
China
Columbia
Croatia
Curacao
Cyprus
Czech Republic
Denmark
Dominican Republic
Ecuador
Egypt, Arab Rep.
Estonia
Eswatini
Ethiopia
Finland
France
Germany
Greece
Honduras
Hungary
Iceland
India
Indonesia
Iran, Islamic Rep.
Ireland
Israel
Italy
Japan
Jordan
Kenya
Korea, Rep.
Kuwait
Latvia
Lebanon
Lithuania
Malaysia
Malta
Mexico
Mozambique
Netherlands
New Zealand
Norway
Oman
Pakistan
Panama
Philippines
Poland
Portugal
Qatar
Romania
San Marino
Saudi Arabia
Singapore
Slovenia
South Africa
Spain
Sweden
Switzerland
Syrian Arab Republic
Taiwan (R.O.C.)
Thailand
Turkiye
Ukraine
United Arab Emirates
United Kingdom
Uruguay
USA
Vietnam
Zimbabwe

 If your country is not listed, please notify us.

 
 

ISBT 128 USER EXPERIENCE

SOFTWARE DEVELOPER

"In addition to being beneficial for donors, patients, and safety, ISBT 128 has been very beneficial for the vendors of IT systems. It enables several IT systems to coexist in a country or a region, since all exchanged blood products are uniformly labeled and carry all relevant information. ISBT 128 reduces vendors' cost since we can focus on one standard when implementing the business logic for products and bedside control. We anticipate future standards for interfacing production equipment."

RENNY SKAGSTAD
CEO  
LabCraft AS 
Oslo, Norway